Failing the Public Health -- Rofecoxib, Merck, and the FDA

doi:10.1056/NEJMp048286

Published at www.nejm.org October 6, 2004 (10.1056/NEJMp048286)

Failing the Public Health -- Rofecoxib, Merck, and the FDA

Eric J. Topol, M.D.

PDF

Purchase this article

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

ABSTRACT

Notice: This article was published early at www.nejm.org toprovide information to physicians and patients who may be reconsideringtheir use of selective inhibitors of cyclooxygenase-2. It willappear in the October 21, 2004, issue of the Journal.

Clickon "PDF" for the full text.

This article has been cited by other articles:

Vasen, H F A, Moslein, G, Alonso, A, Aretz, S, Bernstein, I, Bertario, L, Blanco, I, Bulow, S, Burn, J, Capella, G, Colas, C, Engel, C, Frayling, I, Friedl, W, Hes, F J, Hodgson, S, Jarvinen, H, Mecklin, J-P, Moller, P, Myrhoi, T, Nagengast, F M, Parc, Y, Phillips, R, Clark, S K, de Leon, M P., Renkonen-Sinisalo, L, Sampson, J R, Stormorken, A, Tejpar, S, Thomas, H J W, Wijnen, J (2008). Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57: 704-713 [Abstract] [Full Text]
Carpenter, D., Zucker, E. J., Avorn, J. (2008). Drug-Review Deadlines and Safety Problems. NEJM 358: 1354-1361 [Abstract] [Full Text]
Lee, K. (2008). Has the hunt for conflicts of interest gone too far? No. BMJ 336: 477-477 [Full Text]
Dhalla, I. MD, Laupacis, A. MD MSc (2008). Moving from opacity to transparency in pharmaceutical policy. CMAJ 178: 428-431 [Full Text]
Pearce, N. (2008). Corporate influences on epidemiology. Int J Epidemiol 37: 46-53 [Abstract] [Full Text]
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., Rosenthal, R. (2008). Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy. NEJM 358: 252-260 [Abstract] [Full Text]
Doyle, D. J. (2007). Understanding the open access data movement. Canadian J. Anesthesia 54: 949-950 [Full Text]
Sade, R. M., Grande, D., Gorske, A. L., Campbell, E. G. (2007). A national survey of physician-industry relationships.. NEJM 357: 507-508 [Full Text]
O'Byrne, K. J., Danson, S., Dunlop, D., Botwood, N., Taguchi, F., Carbone, D., Ranson, M. (2007). Combination Therapy With Gefitinib and Rofecoxib in Patients With Platinum-Pretreated Relapsed Non Small-Cell Lung Cancer. JCO 25: 3266-3273 [Abstract] [Full Text]
Abraham, J., Davis, C. (2007). Deficits, Expectations and Paradigms in British and American Drug Safety Assessments: Prising Open the Black Box of Regulatory Science. Science Technology Human Values 32: 399-431 [Abstract]
Cavalieri, T. A. (2007). Managing Pain in Geriatric Patients. JAOA: Journal of the American Osteopathic Association 107: ES10-ES16 [Abstract] [Full Text]
Bennett, C. L., Nebeker, J. R., Yarnold, P. R., Tigue, C. C., Dorr, D. A., McKoy, J. M., Edwards, B. J., Hurdle, J. F., West, D. P., Lau, D. T., Angelotta, C., Weitzman, S. A., Belknap, S. M., Djulbegovic, B., Tallman, M. S., Kuzel, T. M., Benson, A. B., Evens, A., Trifilio, S. M., Courtney, D. M., Raisch, D. W. (2007). Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers. Arch Intern Med 167: 1041-1049 [Abstract] [Full Text]
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., Taubert, K. A. (2007). Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation 115: 1634-1642 [Full Text]
Rostom, A., Dube, C., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M., Moher, D. (2007). Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force. ANN INTERN MED 146: 376-389 [Abstract] [Full Text]
Zarraga, I. G. E., Schwarz, E. R. (2007). Coxibs and Heart Disease: What We Have Learned and What Else We Need to Know. J Am Coll Cardiol 49: 1-14 [Abstract] [Full Text]
Swami, S., Krishnan, A. V., Moreno, J., Bhattacharyya, R. B., Peehl, D. M., Feldman, D. (2007). Calcitriol and Genistein Actions to Inhibit the Prostaglandin Pathway: Potential Combination Therapy to Treat Prostate Cancer. J. Nutr. 137: 205S-210S [Abstract] [Full Text]
Gitlin, J. M., Trivedi, D. B., Langenbach, R., Loftin, C. D. (2007). Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res 73: 227-236 [Abstract] [Full Text]
Ruiz Cantero, M. T., Pardo, M. A. (2006). European Medicines Agency policies for clinical trials leave women unprotected.. J. Epidemiol. Community Health 60: 911-913 [Full Text]
Aberegg, S. K., Arkes, H., Terry, P. B. (2006). Failure to Adopt Beneficial Therapies Caused by Bias in Medical Evidence Evaluation.. Med Decis Making 26: 575-582 [Abstract]
Graham, D. J. (2006). COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk: The Seduction of Common Sense. JAMA 296: 1653-1656 [Full Text]
Bradford, W. D., Kleit, A. N., Nietert, P. J., Steyer, T., McIlwain, T., Ornstein, S. (2006). How Direct-To-Consumer Television Advertising For Osteoarthritis Drugs Affects Physicians' Prescribing Behavior. Health Aff (Millwood) 25: 1371-1377 [Abstract] [Full Text]
Leshnower, B. G., Sakamoto, H., Zeeshan, A., Parish, L. M., Hinmon, R., Plappert, T., Jackson, B. M., Gorman, J. H. III, Gorman, R. C. (2006). Role of acetaminophen in acute myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 290: H2424-H2431 [Abstract] [Full Text]
Brown, S. D., Daly, J. C., Kalish, L. A., McDaniel, S. A. (2006). Financial Disclosures of Scientific Papers Presented at the 2003 RSNA Annual Meeting: Association with Reporting of Non-Food and Drug Administration-approved Uses of Industry Products. Radiology 239: 849-855 [Abstract] [Full Text]
Roth-Cline, M. D. (2006). Clinical Trials in the Wake of Vioxx: Requiring Statistically Extreme Evidence of Benefit to Ensure the Safety of New Drugs. Circulation 113: 2253-2259 [Full Text]
Popp, R. L., Lorell, B. H., Stone, G. W., Laskey, W., Smith, J. J., Kaplan, A. V. (2006). An Outline for Public Registration of Clinical Trials Evaluating Medical Devices. J Am Coll Cardiol 47: 1518-1521 [Abstract] [Full Text]
Sooriakumaran, P (2006). COX-2 inhibitors and the heart: are all coxibs the same?. Postgrad. Med. J. 82: 242-245 [Abstract] [Full Text]
Papanikolaou, P. N., Christidi, G. D., Ioannidis, J. P.A. (2006). Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 174: 635-641 [Abstract] [Full Text]
Ioannidis, J. P.A., Mulrow, C. D., Goodman, S. N. (2006). Adverse events: the more you search, the more you find.. ANN INTERN MED 144: 298-300 [Full Text]
Ray, W. A., Stein, C. M. (2006). Reform of Drug Regulation -- Beyond an Independent Drug-Safety Board. NEJM 354: 194-201 [Full Text]
Abraham, J. (2005). Regulating the drugs industry transparently. BMJ 331: 528-529 [Full Text]
Genuis, S. J. (2005). The Proliferation of Clinical Practice Guidelines: Professional Development or Medicine-by-Numbers?. J Am Board Fam Med 18: 419-425 [Abstract] [Full Text]
Hudson, M., Richard, H., Pilote, L. (2005). Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ 330: 1370- [Abstract] [Full Text]
Freudenberg, N. (2005). Public Health Advocacy to Change Corporate Practices: Implications for Health Education Practice and Research. Health Educ Behav 32: 298-319 [Abstract]
Blackstone, E. H. (2005). Could It Happen Again?: The Bjork-Shiley Convexo-Concave Heart Valve Story. Circulation 111: 2717-2719 [Full Text]
Mello, M. M., Clarridge, B. R., Studdert, D. M. (2005). Academic Medical Centers' Standards for Clinical-Trial Agreements with Industry. NEJM 352: 2202-2210 [Abstract] [Full Text]
Sin, D. D., Man, P., Lacy, P., York, E. (2005). Fluticasone Reduces CRP in COPD. Am. J. Respir. Crit. Care Med. 171: 1191-1192 [Full Text]
Bennett, C. L., Nebeker, J. R., Lyons, E. A., Samore, M. H., Feldman, M. D., McKoy, J. M., Carson, K. R., Belknap, S. M., Trifilio, S. M., Schumock, G. T., Yarnold, P. R., Davidson, C. J., Evens, A. M., Kuzel, T. M., Parada, J. P., Cournoyer, D., West, D. P., Sartor, O., Tallman, M. S., Raisch, D. W. (2005). The Research on Adverse Drug Events and Reports (RADAR) Project. JAMA 293: 2131-2140 [Abstract] [Full Text]
Andreotti, F., Crea, F. (2005). Substandard life-saving drugs: a global concern. Eur Heart J 26: 858-860 [Full Text]
Fredy, J., Diggins, D. A Jr, Morrill, G. B (2005). Blood Pressure in Native Americans Switched from Celecoxib to Rofecoxib. The Annals of Pharmacotherapy 39: 797-802 [Abstract] [Full Text]
Kritchevsky, S. B., Cesari, M., Pahor, M. (2005). Inflammatory markers and cardiovascular health in older adults. Cardiovasc Res 66: 265-275 [Abstract] [Full Text]
Sackner-Bernstein, J. D., Kowalski, M., Fox, M., Aaronson, K. (2005). Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure: A Pooled Analysis of Randomized Controlled Trials. JAMA 293: 1900-1905 [Abstract] [Full Text]
Fukunaga, K., Kohli, P., Bonnans, C., Fredenburgh, L. E., Levy, B. D. (2005). Cyclooxygenase 2 Plays a Pivotal Role in the Resolution of Acute Lung Injury. J. Immunol. 174: 5033-5039 [Abstract] [Full Text]
Bennett, J. S., Daugherty, A., Herrington, D., Greenland, P., Roberts, H., Taubert, K. A. (2005). The Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): A Science Advisory From the American Heart Association. Circulation 111: 1713-1716 [Full Text]
Eisenberg, R. S. (2005). Learning the Value of Drugs -- Is Rofecoxib a Regulatory Success Story?. NEJM 352: 1285-1287 [Full Text]
Solomon, S. D., McMurray, J. J.V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., Bertagnolli, M., the Adenoma Prevention with Celecoxib (APC) Study, (2005). Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. NEJM 352: 1071-1080 [Abstract] [Full Text]
Cavalieri, T. A. (2005). Management of Pain in Older Adults. JAOA: Journal of the American Osteopathic Association 105: 12S-17S [Abstract] [Full Text]
Jain, A., Atreja, A., Harris, C. M., Lehmann, M., Burns, J., Young, J. (2005). Responding to the Rofecoxib Withdrawal Crisis: A New Model for Notifying Patients at Risk and Their Health Care Providers. ANN INTERN MED 142: 182-186 [Abstract] [Full Text]
Khatami, M., Mulshine, J. (2005). Cyclooxygenase Inhibitor Ketorolac or Mast Cell Stabilizers: Immunologic Challenges in Cancer Therapy. Clin. Cancer Res. 11: 1350-1352 [Full Text]
Iadecola, C., Gorelick, P. B. (2005). The Janus Face of Cyclooxygenase-2 in Ischemic Stroke: Shifting Toward Downstream Targets. Stroke 36: 182-185 [Full Text]
Chang, I. J., Harris, R. C. (2005). Are All COX-2 Inhibitors Created Equal?. Hypertension 45: 178-180 [Full Text]
Roden, D. M. (2005). An Underrecognized Challenge in Evaluating Postmarketing Drug Safety. Circulation 111: 246-248 [Full Text]
Topol, E. J. (2005). Arthritis Medicines and Cardiovascular Events--"House of Coxibs". JAMA 293: 366-368 [Full Text]
Rabausch, K., Bretschneider, E., Sarbia, M., Meyer-Kirchrath, J., Censarek, P., Pape, R., Fischer, J. W., Schror, K., Weber, A.-A. (2005). Regulation of Thrombomodulin Expression in Human Vascular Smooth Muscle Cells by COX-2-Derived Prostaglandins. Circ. Res. 96: e1-e6 [Abstract] [Full Text]
Kim, P. S., Reicin, A. S., Villalba, L., Witter, J., Wolfe, M. M., Topol, E. J. (2004). Rofecoxib, Merck, and the FDA. NEJM 351: 2875-2878 [Full Text]
Fontanarosa, P. B., Rennie, D., DeAngelis, C. D. (2004). Postmarketing Surveillance--Lack of Vigilance, Lack of Trust. JAMA 292: 2647-2650 [Full Text]
(2004). The Next Chapter in the COX-2 Saga. Journal Watch Cardiology 2004: 2-2 [Full Text]
(2004). Perspective on the Vioxx Recall. JWatch General 2004: 1-1 [Full Text]

Comments and questions? Please contact us.